Jonah Feldman

Articles

Giredestrant-Based Combo Boosts PFS Across Subgroups in Advanced ER+/HER2– Breast Cancer After CDK4/6 Inhibition

December 12th 2025

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC

December 12th 2025

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

Pelabresib Plus Ruxolitinib Bests Ruxolitinib Monotherapy in JAK Inhibitor-Naive Myelofibrosis

December 9th 2025

Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Axatilimab Shows Long-Term Safety and Clinical Benefit in Pretreated Chronic GVHD

December 9th 2025

Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.

GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL

December 9th 2025

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC

October 19th 2025

The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.

ASCT Plus Isa-KRd Consolidation Does Not Boost MRD Negativity Rates in Myeloma

June 4th 2025

ASCT added to Isa-KRd consolidation following Isa-KRd induction did not improve MRD outcomes vs continued Isa-KRd in MRD-negative, newly diagnosed myeloma.

Elraglusib Plus Chemotherapy Extends OS in Untreated Metastatic Pancreatic Ductal Adenocarcinoma

June 1st 2025

Elraglusib plus gemcitabine/nab-paclitaxel displayed an OS benefit vs chemotherapy alone in untreated metastatic pancreatic ductal adenocarcinoma.

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

June 1st 2025

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

Ruxolitinib Plus SOC Prophylaxis Is Associated With Lower Rates of GVHD in Myelofibrosis

February 14th 2025

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD

February 14th 2025

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

December 12th 2024

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

December 10th 2024

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

December 9th 2024

Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.

Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor–Naive Myelofibrosis

December 9th 2024

Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

September 27th 2024

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

September 27th 2024

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

Darolutamide Plus ADT Improves rPFS in mHSPC

September 16th 2024

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

T-DXd Delays Time to Deterioration in Functioning, Pain in HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

September 15th 2024

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.